Skip to main content

Treatment Clinical Trials for Breast Cancer

Review the breast cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 451-475 of 480

Cryoablation of Small Breast Tumors in Early Stage Breast Cancer
Status: Active
Location: See ClinicalTrials.gov
Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy
Status: Enrolling by Invitation
Location: 2 locations
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Status: Enrolling by Invitation
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Combination Study of SV-BR-1-GM With Retifanlimab
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
Postoperative Circulating Tumor Deoxyribonucleic Acid (ctDNA) Surveillance to Guide the Treatment of Early-Stage Triple Negative Breast Cancer Patients with Residual Disease, PREDICT-RD Trial
Status: Approved
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Status: Approved
Location: OHSU Knight Cancer Institute, Portland, Oregon
Non-surgical Approach (Radiation Therapy) for the Treatment of Early Stage Breast Cancer Patients with an Exceptional Response to Neoadjuvant Chemotherapy, NoCUT-BC Trial
Status: Approved
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A Cancer Vaccine (STEMVAC) in Combination with Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Taletrectinib for the Treatment of Patients with CDH1-Mutated, Metastatic Invasive Lobular Breast Cancer, TaCe-1 Trial
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
Status: Temporarily Closed to Accrual
Location: 704 locations
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in Patients with Breast Cancer
Status: Temporarily Closed to Accrual
Location: 4 locations
Pembrolizumab in Treating Patients with Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
ARX788 for Treating Patients with HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: University of California San Francisco, San Francisco, California
Sacituzumab Govitecan and Trastuzumab for the Treatment of HER2+ Metastatic Breast Cancer after Progression on Enhertu, SATEEN Trial
Status: Temporarily Closed to Accrual
Location: 6 locations
Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin for the Treatment of Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Pembrolizumab in Treating Patients with Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Brain-Directed Stereotactic Radiation Therapy with or without AGulX Gadolinium-Based Nanoparticles for the Treatment of Brain Metastases
Status: Temporarily Closed to Accrual
Location: 2 locations
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
A Vaccine (H2NVAC) before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Status: Temporarily Closed to Accrual
Location: 2 locations
mRNA-2752 with or without a PD1 Inhibitor in Treating Patients with High Grade Ductal Breast Carcinoma In Situ
Status: Temporarily Closed to Accrual
Location: 2 locations